Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder

Date: July 29, 2019 Issue #:  1577Summary:  The FDA has approved bremelanotide (Vyleesi– Amag), a melanocortin receptor agonist, for subcutaneous treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Bremelanotide is not approved for use in men or postmenopausal women. It is the second drug to be approved in the US for this indication; flibanserin(Addyi), which was approved in 2015, was the first.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Addyi bremelanotide female sexual dysfunction flibanserin Vyleesi Source Type: research